Today we announced the presentation of long-term durability data from the Phase 3 ENVISION trial for patients with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC) at SUO 2024. Learn more: https://bit.ly/4ip9QYw
UroGen Pharma’s Post
More Relevant Posts
-
Passionate Medical Oncologist | Lecturer at National Cancer Institute | ESMO Certified | ESCO Graduate |ESGO member| ASCO Member | ESO Ambassador | Dedicated to Improving Patient QOL and Outcomes.
1st ADC in ovarian cancer
Mirvetuximab soravtansine monotherapy led to an objective response rate of 51.9% in heavily pretreated patients with FRα+, platinum-sensitive ovarian cancer, meeting the primary end point of the phase 2 PICCOLO trial. #GYNCSM https://lnkd.in/eJtiWjfe
-
Join us TODAY at 2:30PM UTC to hear Professor Sudha Sundar present groundbreaking findings from the ROCkeTS Study, showcasing how symptom-triggered testing can detect early-stage ovarian cancer and improve outcomes. Register here: https://loom.ly/kMT9ZYU #NoWomanLeftBehind #NoPersonLeftBehind #EarlyDetection #OvarianCancerResearch
-
Today, Friday October 18, is National Mammography Day, as a reminder of the importance of early detection in the fight against breast cancer. Regular mammograms can save lives by detecting breast cancer early, when it is most treatable. #NationalMammographyDay
-
-
The phase 2/3 ASPEN-06 trial showed improved clinical responses and survival outcomes with evorpacept in patients with HER2-positive gastric/gastroesophageal cancer, compared to paclitaxel (TRP) alone. To learn more, visit: https://ow.ly/l69X50UNXl0
-
In this episode of #OncLiveOnAir, Dr Brown discusses the rationale for the RAMP-301 trial of avutometinib plus defactinib in low-grade serous ovarian cancer. #OvarianCancer https://lnkd.in/eXVhV6_B
-
-
Are you aware of your breast density level? My Density Matters is on a mission to empower women to learn their breast density and proactively manage their breast cancer screening. Please mark your calendars for February 19th and stay tuned for further updates. #mydensitymatters #checkyourchart #accelerateaction
-
-
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer: https://lnkd.in/g7V9FUxp
-
-
We’re studying ANKTIVA® in combination with the current standard of care vs. standard of care as first-line treatment for patients with stage 3 or 4 non-small cell lung cancer (NSCLC). Learn more about our phase 3 trial: https://lnkd.in/gjHm-nak
-
In recent years, EGFR inhibitors have become available to additional patients with EGFR-mutated lung cancer, including those with early-stage or newly diagnosed disease. Learn about the approved indications in this schematic and by visiting the #AACRBlog: https://bit.ly/4g1o6W0
-
-
a session of management of metastatic triple negative breast cancer : current therapies and future Horizons from IVPN-Network, FZ, LLE
-
